Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single-Ascending Doses of PGN-EDODM1 in Adult Participants With Myotonic Dystrophy Type 1 (FREEDOM-DM1)

NCT06204809 is registered in ClinicalTrials.gov with PepGen Inc as lead sponsor.

NCT NCT06204809
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06204809 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single-Ascending Doses of PGN-EDODM1 in Adult Participants With Myotonic Dystrophy Type 1 (FREEDOM-DM1)
Lead sponsor
PepGen Inc
Phase
Phase 1
Overall status
Completed
Start date
December 12, 2023
Completion date
October 28, 2025
Enrollment
24 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

myotonic dystrophy 1